Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ESMO open [ESMO Open] NLMUID: 101690685"" wg kryterium: JN


Tytuł :
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.
Autorzy :
Di Noia V; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: .
D'Aveni A; Department of Medical Oncology 1, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
D'Argento E; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Rossi S; Department of Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.
Ghirardelli P; Department of Medical Oncology 1, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Bortolotti L; Department of Medical Oncology 1, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Vavassori V; Department of Medical Oncology 1, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Istituto di Medicina Interna e Geriatria, Università; Cattolica del Sacro Cuore, Rome, Italy.
Ceresoli GL; Department of Medical Oncology 1, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Oct 08; Vol. 6 (6), pp. 100280. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5).
Autorzy :
Tanaka Y; Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Takeuchi H; Department of Surgery, School of Medicine, Hamamatsu University, Hamamatsu, Japan.
Nakashima Y; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nagano H; Gastroenterological, Breast and Endocrine Surgery, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
Ueno T; Department of Dentistry, National Cancer Center Hospital, Tokyo, Japan.
Tomizuka K; Department of Dentistry, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Morita S; Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Emi Y; Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Hamai Y; Department of Surgical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Hihara J; Department of Surgery, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Saeki H; Department of General Surgical Science, Gunma University, Maebashi, Japan.
Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kunisaki C; Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan.
Otsuji E; Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Baba H; Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
Matsubara H; Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Maehara Y; Director, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
Kitagawa Y; Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yoshida K; Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Oct 06; Vol. 6 (5), pp. 100277. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Autorzy :
Serna-Blasco R; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Sánchez-Herrero E; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Atrys Health, Barcelona, Spain.
Sanz-Moreno S; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Rodriguez-Festa A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
García-Veros E; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Casarrubios M; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Sierra-Rodero B; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Laza-Briviesca R; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Cruz-Bermúdez A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain.
Mielgo-Rubio X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
Sánchez-Hernández A; Medical Oncology Department, Hospital Provincial Centre de Castelló, Castellón de la Plana, Castellón, Spain.
Uribelarrea EA; Medical Oncology Department, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.
Calvo V; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
Romero A; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Electronic address: .
Provencio M; Molecular Oncology Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Spain; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Oct 01; Vol. 6 (5), pp. 100279. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Autorzy :
Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: .
Ciuleanu TE; Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
Cobo M; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
Schenker M; Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania.
Zurawski B; Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
Menezes J; Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Richardet E; Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.
Bennouna J; Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.
Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona.
Juan-Vidal O; Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.
Alexandru A; Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.
Sakai H; Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
Lingua A; Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina.
Reyes F; Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile.
Souquet PJ; Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France.
De Marchi P; Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.
Martin C; Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Pérol M; Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France.
Scherpereel A; Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France.
Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.
Carbone DP; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA.
Memaj A; Bristol Myers Squibb, Princeton, USA.
Marimuthu S; Bristol Myers Squibb, Princeton, USA.
Zhang X; Bristol Myers Squibb, Princeton, USA.
Tran P; Bristol Myers Squibb, Princeton, USA.
John T; Department of Medical Oncology, Austin Hospital, Heidelberg, Australia.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Oct 01; Vol. 6 (5), pp. 100273. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review.
Autorzy :
Garutti M; CRO Aviano National Cancer Institute IRCCS, Aviano, Italy. Electronic address: .
Lambertini M; Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
Puglisi F; CRO Aviano National Cancer Institute IRCCS, Aviano, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medicine (DAME), University of Udine, Udine, Italy.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 28; Vol. 6 (5), pp. 100276. Date of Electronic Publication: 2021 Sep 28.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment.
Autorzy :
Grinshpun A; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Rottenberg Y; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Ben-Dov IZ; Faculty of Medicine, The Hebrew University, Jerusalem, Israel; Department of Nephrology and Hypertension, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Djian E; Faculty of Medicine, The Hebrew University, Jerusalem, Israel; Clinical Virology Unit, Department of Microbiology and Infectious Disease, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Wolf DG; Faculty of Medicine, The Hebrew University, Jerusalem, Israel; Clinical Virology Unit, Department of Microbiology and Infectious Disease, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Kadouri L; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Faculty of Medicine, The Hebrew University, Jerusalem, Israel. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 27; Vol. 6 (6), pp. 100283. Date of Electronic Publication: 2021 Sep 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050) .
Autorzy :
Gaspar N; Department of Childhood and Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: .
Campbell-Hewson Q; The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
Gallego Melcon S; Pediatric Oncology and Hematology Service, University Hospital Vall d'Hebron, Barcelona, Spain.
Locatelli F; Department of Pediatric Hematology and Oncology, Ospedale Pediatrico Bambino Gesù, University of Rome, Rome, Italy.
Venkatramani R; Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA.
Hecker-Nolting S; Department of Pediatric Oncology, Hematology, Immunology, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
Gambart M; Pediatric Hemato-Oncology Unit, CHU Toulouse - Hôpital des Enfants, URCP, Toulouse, France.
Bautista F; Paediatric Haematology-Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Thebaud E; Pediatric Oncology-Hematology and Immunology Department, CHU Nantes - Hôpital Mère-Enfant, Nantes, France.
Aerts I; SIREDO Oncology Center, Institut Curie, PSL Research University, Paris, France.
Morland B; Department of Paediatric Hematology/Oncology, Birmingham Children's Hospital, Birmingham, UK.
Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
Canete Nieto A; Children's Oncology Unit, Pediatric Service, Hospital Universitario y Politecnico La Fe, Valencia, Spain.
Longhi A; Chemotherapy Service, Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy.
Lervat C; Pediatric and AYA Oncology Unit, Centre Oscar Lambret Lille, Lille, France.
Entz-Werle N; Pediatric Onco-Hematology Unit, Chu Strasbourg-Hôpital Hautepierre, Strasbourg, France.
Strauss SJ; Clinical Research Facility, University College London Hospitals NHS Trust, London, UK.
Marec-Berard P; Institute of Pediatric Hematology and Oncology, Centre Léon Bérard, Lyon, France.
Okpara CE; Clinical Research, Oncology Business Group, Eisai Ltd., Hatfield, UK.
He C; Biostatistics, Oncology Business Group, Eisai Inc., Woodcliff Lake, USA.
Dutta L; Clinical Research, Oncology Business Group, Eisai Inc., Woodcliff Lake, USA.
Casanova M; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 22; Vol. 6 (5), pp. 100250. Date of Electronic Publication: 2021 Sep 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
Autorzy :
Bordonaro R; Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy. Electronic address: .
Calvo A; Gregorio Marañon University General Hospital, Madrid, Spain.
Auriemma A; Azienda Ospedaliera Universitaria Integrat, University of Verona, Verona, Italy.
Hollebecque A; Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.
Rubovszky G; Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology Hungary, Budapest, Hungary.
Saunders MP; Christie NHS Foundation Trust, Manchester, UK.
Pápai Z; Department of Medical Oncology, Duna Medical Centre, Budapest, Hungary.
Prager G; Comprehensive Cancer Centre Vienna, Medical University Vienna, Austria.
Stein A; UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany.
André T; Sorbonne Université et Hôpital Saint-Antoine, Service d'Oncologie Médicale, Paris, France.
Argilés G; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
Cubillo A; Medical Oncology, Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal, Madrid, Spain.
Dahan L; Aix Marseille University; Assistance Publique Hôpitaux de Marseille, Centre d'Essais Précoces en Cancérologie de Marseille CLIP, Marseille, France.
Edeline J; Department of Medical Oncology, Centre Eugene Marquis, ARPEGO network, Rennes, France.
Leger C; Institut de Recherches Internationales Servier, Suresnes, France.
Cattan V; Institut de Recherches Internationales Servier, Suresnes, France.
Fougeray R; Institut de Recherches Internationales Servier, Suresnes, France.
Amellal N; Institut de Recherches Internationales Servier, Suresnes, France.
Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 18; Vol. 6 (5), pp. 100270. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
Autorzy :
Planchard D; Institut Gustave Roussy, Department of Medical Oncology, Thoracic Oncology Unit, Villejuif, France. Electronic address: .
Feng PH; Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
Karaseva N; City Clinical Oncology Dispensary, St. Petersburg, Russia.
Kim SW; Asan Medical Center, Seoul, Republic of Korea.
Kim TM; Seoul National University Hospital, Seoul, Republic of Korea.
Lee CK; Clinical Research Unit, Division of Cancer Services, St. George Hospital, Kogarah, Australia.
Poltoratskiy A; Department of Clinical Trials, Petrov Research Institute of Oncology, St. Petersburg, Russia.
Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Marshall R; AstraZeneca, Cambridge, UK.
Huang X; AstraZeneca, Cambridge, UK.
Howarth P; AstraZeneca, Cambridge, UK.
Jänne PA; Dana-Farber Cancer Institute, Boston, USA.
Kobayashi K; Department of Respiratory Medicine, Saitama Medical School International Medical Center, Saitama, Japan.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 17; Vol. 6 (5), pp. 100271. Date of Electronic Publication: 2021 Sep 17.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.
Autorzy :
Hou N; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wu J; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Xiao J; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wang Z; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Song Z; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Ke Z; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wang R; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wei M; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Xu M; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wei J; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Qian X; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Xu X; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Yi J; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wang T; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Zhang J; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Li N; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Fan J; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Hou G; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China.
Wang Y; Department of Geriatrics, Union Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, PR China.
Wang Z; Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China. Electronic address: .
Ling R; Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 16; Vol. 6 (5), pp. 100269. Date of Electronic Publication: 2021 Sep 16.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
Autorzy :
Kulkarni AA; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, USA.
Rubin N; Biostatistics Core, Masonic Cancer Center, Minneapolis, USA.
Tholkes A; Clinical and Translational Science Institute, University of Minnesota, Minneapolis, USA.
Shah S; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, USA.
Ryan CJ; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, USA.
Lutsey PL; Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, USA.
Prizment A; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, USA.
Rao A; Division of Hematology and Oncology, Baylor College of Medicine, Houston, USA. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 09; Vol. 6 (5), pp. 100261. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.
Autorzy :
Younger E; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Jones RL; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, Institute of Cancer Research, London, UK.
den Hollander D; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Soomers VLMN; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Desar IME; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Benson C; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK.
Young RJ; Academic Unit of Clinical Oncology, The University of Sheffield, Sheffield, UK.
Oosten AW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
de Haan JJ; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Miah A; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, Institute of Cancer Research, London, UK.
Zaidi S; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Husson O; Division of Clinical Studies, Institute of Cancer Research, London, UK; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: .
van der Graaf WTA; Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 09; Vol. 6 (5), pp. 100258. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Autorzy :
Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Omarini C; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
Diodati L; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Palleschi M; Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Meattini I; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Lorenzini G; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Isca C; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
Fontana A; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Livi L; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Piacentini F; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
Fogli S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
De Giorgi U; Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 09; Vol. 6 (5), pp. 100231. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Autorzy :
Peeters M; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem, Belgium. Electronic address: .
Verbruggen L; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Teuwen L; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Vanhoutte G; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Vande Kerckhove S; SD Infectious Diseases in Humans, Service Immune response, Sciensano, Brussels, Belgium.
Peeters B; Department of Laboratory Medicine, Antwerp University Hospital, Edegem, Belgium.
Raats S; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Van der Massen I; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
De Keersmaecker S; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Debie Y; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Huizing M; Biobank Antwerp, Edegem, Belgium.
Pannus P; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Neven K; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Ariën KK; Virology Unit, Institute of Tropical Medicine Antwerp, Antwerp, Belgium; Department of Biomedical Sciences, University of Antwerp, Edegem, Belgium.
Martens GA; Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.
Van Den Bulcke M; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Roelant E; Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, Belgium; StatUa, Center for Statistics, University of Antwerp, Antwerp, Belgium.
Desombere I; SD Infectious Diseases in Humans, Service Immune response, Sciensano, Brussels, Belgium.
Anguille S; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Goossens M; SD Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Vandamme T; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
van Dam P; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 08; Vol. 6 (5), pp. 100274. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Refining patient selection for breast cancer immunotherapy: beyond PD-L1.
Autorzy :
Kossai M; Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France.
Radosevic-Robin N; Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France. Electronic address: .
Penault-Llorca F; Department of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 03; Vol. 6 (5), pp. 100257. Date of Electronic Publication: 2021 Sep 03.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Immune checkpoint inhibitor administration during pregnancy: a case series.
Autorzy :
Andrikopoulou A; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Korakiti AM; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Apostolidou K; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Zagouri F; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 03; Vol. 6 (5), pp. 100262. Date of Electronic Publication: 2021 Sep 03.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Autorzy :
Kirchner M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Kluck K; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Brandt R; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Volckmar AL; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Penzel R; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Kazdal D; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany.
Endris V; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Neumann O; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Seker-Cin H; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Goldschmid H; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Glade J; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Allgäuer M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Kriegsmann M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany.
Winter H; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; Department of Thoracic Surgery, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Muley T; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Perner S; Pathology of the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck and the Research Center Borstel, Borstel, Germany; Airway Research Center North (ARCN), Borstel, Germany.
Frost N; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health, Berlin, Germany.
Reck M; Airway Research Center North (ARCN), Borstel, Germany; Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, Germany.
Fröhling S; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Schirmacher P; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Thomas M; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany.
Budczies J; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany.
Christopoulos P; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany. Electronic address: .
Stenzinger A; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 03; Vol. 6 (5), pp. 100253. Date of Electronic Publication: 2021 Sep 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
Autorzy :
Kim JH; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim SH; Pathology Center, Seegene Medical Foundation, Seoul, Republic of Korea.
Jeon MK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim JE; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Kim KH; Division of Medical Oncology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, Republic of Korea.
Yun KH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Korea 21 PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jeung HC; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ahn JH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Electronic address: .
Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 02; Vol. 6 (5), pp. 100249. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
How we treat HER2-positive brain metastases.
Autorzy :
Stavrou E; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA. Electronic address: .
Winer EP; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA.
Lin NU; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, USA.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 02; Vol. 6 (5), pp. 100256. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Autorzy :
Klinghammer K; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité Comprehensive Cancer Center, Berlin, Germany. Electronic address: .
Fayette J; Medical Oncology, Centre Léon Bérard, Lyon, France.
Kawecki A; Cancer Center-Maria Sklodowska-Curie Memorial Institute, Warsaw, Poland.
Dietz A; University of Leipzig, Leipzig, Germany; Outpatient Chemotherapy, University of Leipzig, Leipzig, Germany.
Schafhausen P; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Folprecht G; University Hospital Carl Gustav Carus, Dresden, Germany.
Rottey S; Ghent University Hospital, Department of Medical Oncology, Ghent, Belgium.
Debourdeau P; Institut Sainte-Catherine, Avignon, France.
Lavernia J; F.I.V.O., Valencia, Spain.
Jacobs A; Premier Research, Reading, UK.
Ahrens-Fath I; Glycotope GmbH, Berlin, Germany.
Dietrich B; Glycotope GmbH, Berlin, Germany.
Baumeister H; Glycotope GmbH, Berlin, Germany.
Zurlo A; Glycotope GmbH, Berlin, Germany.
Ochsenreither S; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité Comprehensive Cancer Center, Berlin, Germany.
Keilholz U; Charité Comprehensive Cancer Center, Berlin, Germany.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2021 Sep 02; Vol. 6 (5), pp. 100242. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies